United Therapeutics Co. (UTHR) Given Consensus Rating of “Hold” by Brokerages

Shares of United Therapeutics Co. (NASDAQ:UTHR) have received a consensus rating of “Hold” from the fourteen ratings firms that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $140.27.

A number of equities analysts have issued reports on the company. ValuEngine raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 26th. Zacks Investment Research raised United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price target for the company in a research note on Monday, January 15th. HC Wainwright reaffirmed a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a research note on Thursday, October 26th. Credit Suisse Group reaffirmed an “underperform” rating and set a $118.00 price target on shares of United Therapeutics in a research note on Thursday, January 18th. Finally, BidaskClub lowered United Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th.

In other United Therapeutics news, Director Christopher Causey sold 580 shares of the stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $134.72, for a total transaction of $78,137.60. Following the transaction, the director now directly owns 1,555 shares of the company’s stock, valued at $209,489.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 1,253 shares of the stock in a transaction on Friday, November 24th. The stock was sold at an average price of $124.07, for a total transaction of $155,459.71. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,136 shares of company stock valued at $1,248,989. 7.80% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. KBC Group NV grew its position in shares of United Therapeutics by 3.5% in the third quarter. KBC Group NV now owns 22,974 shares of the biotechnology company’s stock valued at $2,692,000 after purchasing an additional 783 shares during the last quarter. California Public Employees Retirement System grew its position in shares of United Therapeutics by 1.5% in the third quarter. California Public Employees Retirement System now owns 133,793 shares of the biotechnology company’s stock valued at $15,679,000 after purchasing an additional 1,993 shares during the last quarter. Swiss National Bank grew its position in United Therapeutics by 1.0% during the third quarter. Swiss National Bank now owns 165,600 shares of the biotechnology company’s stock worth $19,407,000 after buying an additional 1,600 shares in the last quarter. Van ECK Associates Corp grew its position in United Therapeutics by 9.4% during the third quarter. Van ECK Associates Corp now owns 123,100 shares of the biotechnology company’s stock worth $14,426,000 after buying an additional 10,598 shares in the last quarter. Finally, Wedbush Securities Inc. acquired a new stake in United Therapeutics during the third quarter worth about $435,000.

Shares of United Therapeutics (NASDAQ:UTHR) traded down $0.33 during mid-day trading on Tuesday, reaching $129.17. The company had a trading volume of 327,749 shares, compared to its average volume of 403,918. United Therapeutics has a 1-year low of $112.01 and a 1-year high of $169.89. The company has a market cap of $5,561.69, a price-to-earnings ratio of 11.42 and a beta of 1.26.

WARNING: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/13/united-therapeutics-co-uthr-given-consensus-rating-of-hold-by-brokerages.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply